All In Biotech

Drug Trial Radar · NCT05543174

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7

Actual

Start

Jan 16, 2023

Primary completion

Oct 25, 2023

Study completion Jul 25, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-625 for up to the end of study (about 34 months). Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

Conditions

  • Alagille Syndrome (ALGS)

Interventions

  • TAK-625Drug

    TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22Time frame: From Week 18 to Week 22

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Kyoto University Hospital

    Kyoto, Japan

  • Saitama Prefectural Children's Medical Center

    Saitama, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan

  • Yokohamashi Tobu Hospital

    Yokohama, Kanagawa, Japan

  • Miyagi Children's Hospital

    Sendai, Miyagi, Japan

  • Kindai University Nara Hospital

    Ikoma, Nara, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.